Challenging the notion that prolonged protein kinase inhibition is required to translate into efficacy, Shah et al. reported that transient potent BCR-ABL inhibition by dasatinib induces apoptotic pathways in chronic myeloid leukemia cells [21]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.